141388-76-3

Yellow to slightly yellow crystalline powder

ChEBI: Besifloxacin is a member of quinolines.

An amino-azepinyl quinolone formulated as a suspension for ophthalmic usage. It exhibits good antistaphylococcal activity, as well as activity against Str. pneumoniae, Enterobacteriaceae, H. influenzae and Mor. catarrhalis. It is weakly active against Corynebacterium spp. and has no useful activity against Ps. aeruginosa. After instillation into the eye, less than 0.1% of the drug reaches the plasma. It is used for bacterial conjunctivitis.

This fourth-generation, fluoroquinolone-class antibi?otic (FW = 393.84 g/mol; CAS 141388-76-3), also known as Besivance, BOL-303224-A, SS734, and 7-[ (3R) -3-aminoazepam-1-yl]-8-chloro-1-cyclopropyl-6-fluoro- 4-oxo-1,4-dihydroquinoline-3-carboxylic acid, displays activity in in vitro antimicrobial efficacy studies as well as efficacy in an in vivo murine infection model. BOL-303224-A demonstrates excellent ocular pharmacokinetics in rabbits, with ocular mean residence times >7 hours, reaching conjunctival concentrations that exceed the MIC90 for nonresistant ophthalmic isolates for >12 hours following a single dose. Besifloxacin acts as an anti-inflammatory agent in monocytes in vitro, a property that may enhance its efficacy in ocular infections. It exhibits broad-spectrum in vitro activity against aerobic and anaerobic bacteria, based on studies on 2,690 clinical isolates representing 40 species.